Two big pharma stories are driving markets today. JNJ won a new FDA approval for TREMFYA in psoriatic arthritis, adding to its label and lifting options activity on the call side. Short interest sits at just 0.9% of free float — this stock is not a bear target. PFE sealed a deal with Innovent to develop 12 new cancer treatments globally. Analysts will watch both names closely heading into June.
California Governor Gavin Newsom escalated his feud with Elon Musk today. He called out Tesla and SpaceX as products of California's ecosystem — and floated a notional $1 trillion bill. Options activity on TSLA remains heavy across near-term expiries. Short interest is low at 2.7% of free float. The market is watching headlines, not positioning for a squeeze.
NetApp was the standout on the analyst desk. Its average target jumped 13% to $137.53 after strong quarterly results. went the other way — downgraded, with consensus target barely moving at $146.71. Short interest at 19.2% of free float signals lingering bearish sentiment.
On the short interest front, Wolfspeed remains the most extreme case. SI hit 134% of free float this week. Availability is zero. Bears have locked up every borrowable share.
ULTA Beauty and Dollar General report Monday. Medtronic and Macy's follow Tuesday. The week ahead is heavy on consumer and healthcare reads — two sectors where short interest has been building steadily.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
